Tech Tactics: Vicci Eyewear Looks to Seek AI for Online Growth and a ‘Data-Driven Culture'
Vicci Eyewear is on a mission to boost its e-commerce business with help from a new artificial intelligence (AI) partner.
More from Sourcing Journal
Upstream Focus: Do-Gree Fashions Ltd.'s Matthew Tock on Tariffs, Taking Risks and Transparency
Chain Reaction: NuVizz CEO Guru Rao on Surviving Disruption with Smarter Delivery Tech
Walmart US Nearly Doubled Deliveries Made in Three Hours or Less
Last week, the Miami-based prescription eyewear brand announced a partnership with Seek AI, a multi-agent system designed to deliver accurate, understandable and secure autonomous analytics for both data teams and non-technical users. By leveraging Seek AI's agentic tools—an advanced form of AI that operates autonomously to make decisions and take action toward specific goals—Vicci Eyewear plans to enhance its data strategy and accelerate online growth.
'Seek gave me data I could confidently put in front of investors. Instead of rough estimates, I had real metrics—average order value, return rates [and] conversion data—all backed by our own sources,' said Steven Geduld, CEO at Vicci Eyewear. 'That level of detail saved me time and added credibility. I'm excited to have Seek help Vicci drive a data-driven culture.'
To achieve these results, Vicci Eyewear is leveraging Seek's suite of solutions. This includes the Dialogue Agent, which allows both data teams and non-technical users to interact with structured data through natural language queries, and the Explanation Agent, which analyzes query results and provides clear, summarized insights.
By combining Seek's managed services, brands like Vicci Eyewear can unlock more advanced reasoning and problem-solving capabilities tailored to their business goals, according to the New York-based company.
'We are excited to partner with Vicci Eyewear and implement our Seek AI agentic data platform to deliver faster speed to meaningful insights,' said Sarah Nagy, CEO at Seek AI. 'In today's world, the retailer with the best data-driven edge will be best equipped to navigate toward better business outcomes, and our Seek data agents are ready to meet that need.'
While this marks the first collaboration between Vicci Eyewear and Seek AI, the software company has already helped several other retailers drive measurable improvements since its founding in 2021.
One recent example is Welles, a sustainable clothing brand that used Seek AI's tools to transform its e-commerce operations. Within one month, Welles saved 30 minutes per day on data-related tasks, re-engaged over 4,000 dormant customers and reduced product returns by 50 percent.
'Seek AI has been transformative for our operations,' said Rachel Rothenberg-Saenz, co-founder and CEO of Welles. 'We saw measurable results almost immediately—recovering potential sales, reducing returns and gaining actionable insights that validate our marketing and operational decisions. It's the clarity and efficiency we needed to scale smarter.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Which ETF Has the Highest Dividend Yield in 2025? And Is It a Buy Now?
Exchange-traded funds typically hold baskets of stocks, but trade like individual equities. The Invesco KBW Premium Yield Equity REIT ETF focuses on real estate investment trusts. REITs are required to distribute most of their profits via dividends. 10 stocks we like better than Invesco Exchange-Traded Fund Trust II - Invesco Kbw Premium Yield Equity REIT ETF › Exchange-traded funds (ETFs) have become quite popular in their three-plus decades of existence. There are now more publicly listed ETFs than there are individual stocks on the New York Stock Exchange. Similar to mutual funds, ETFs usually hold baskets of stocks or other assets, but they trade similarly to stocks. They are highly liquid, and owning them can be a more tax-efficient way to invest than holding mutual funds. Each ETF is designed around a theme -- and that could be anything from tracking an index to focusing on one industry or type of stock. Many have portfolios that are intended to produce reliable dividends for income investors. But which ETF has the highest yield in 2025? At this point, investors can find ETFs to suit pretty much any investment strategy. Some track indexes, others are actively managed, and many deploy complex options strategies or leverage up on crypto bets. However, because many of those strategies result in funds that are not appropriate as long-term holdings, I'm excluding ETFs that use complex options strategies or make big crypto bets from my search. Within the field of choices that remain, the highest-yielding ETF at the moment is the Invesco KBW Premium Yield Equity REIT ETF (NASDAQ: KBWY). It invests solely in real estate investment trusts (REITs) -- companies with special structures that enjoy tax advantages as long as they abide by the required policies. For instance, a REIT must distribute 90% of its taxable income to its shareholders each year through dividends. REITs also must invest at least 75% of their assets in real estate or cash, and receive at least 75% of their total income from real estate revenue, like rent, mortgage interest, real estate loans, or the sale of real estate assets. Because of that payout requirement, REITs are viewed as strong dividend investments. However, their earnings and yields can fluctuate as the real estate market progresses through economic and interest rate cycles. KBWY's dividends have had their ups and downs, but it has had a strong average yield since launching in 2010. Currently, its yield is over 9.6%. As of July 7, the ETF's top 10 holdings by weight were: KBWY ETF Top 10 Holdings Portfolio Weight 1. Brandywine Realty Trust (NYSE: BDN) 6.27% 2. Innovative Industrial Properties (NYSE: IIPR) 6.20% 3. Community Healthcare Trust (NYSE: CHCT) 5.26% 4. Park Hotels & Resorts (NYSE: PK) 4.51% 5. Global Medical REIT (NYSE: GMRE) 4.43% 6. Global Net Lease (NYSE: GNL) 4.28% 7. Healthcare Realty Trust (NYSE: HR) 4.22% 8. Easterly Government Properties (NYSE: DEA) 3.94% 9. Apple Hospitality REIT (NYSE: APLE) 3.88% 10. RLJ Lodging Trust (NYSE: RLJ) 3.85% Source: Invesco. Brandywine Realty Trust focuses on urban and municipal transit-oriented developments. Innovative Industry Properties leases properties to companies in the cannabis sector. Community Healthcare Trust leases properties to hospitals and other healthcare providers, primarily in markets outside of major cities. Few ETFs that don't make use of super-aggressive investment strategies can match KBWY's yield. But in the world of dividends, investors should always take a skeptical approach to an unusually high yield -- sometimes, they're too good to last. And sometimes, they signal that an investment has other problems. For example, since its inception, KBWY's net asset value (NAV) is only up about 4%. Now, part of that weak result can be attributed to the pandemic, which changed the ways people live and work, likely forever. As a result, many real estate stocks and REITs got hit hard and haven't recovered. That's reflected in KBWY's five-year performance. A lower interest rate environment, which many expect to start to materialize later this year, could help KBWY by lowering REITs' borrowing costs and improving conditions for the businesses that are leasing space. Lower benchmark interest rates also reduce the amount that investors can earn from low-risk assets, which makes dividend investments more appealing. However, one thing that worries me about KBWY is its high exposure to the office space and healthcare segments, both of which have been shaky since the pandemic, and which are still very much trying to find their footing. Although KBWY's yields have been attractive since its inception, the dividend is likely to remain volatile, and it likely won't be this high forever. KBWY will keep churning out passive income for its shareholders, but I think there are more stable options out there that might be more prudent for income-focused investors. Before you buy stock in Invesco Exchange-Traded Fund Trust II - Invesco Kbw Premium Yield Equity REIT ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Invesco Exchange-Traded Fund Trust II - Invesco Kbw Premium Yield Equity REIT ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool recommends Easterly Government Properties and Innovative Industrial Properties. The Motley Fool has a disclosure policy. Which ETF Has the Highest Dividend Yield in 2025? And Is It a Buy Now? was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
JPMorgan Chase (JPM) To Report Earnings Tomorrow: Here Is What To Expect
Global financial services giant JPMorgan Chase (NYSE:JPM) will be reporting results this Tuesday morning. Here's what to expect. JPMorgan Chase beat analysts' revenue expectations by 5.6% last quarter, reporting revenues of $46.01 billion, up 9.7% year on year. It was a strong quarter for the company, with a decent beat of analysts' EPS estimates and tangible book value per share in line with analysts' estimates. Is JPMorgan Chase a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting JPMorgan Chase's revenue to decline 13.1% year on year to $43.61 billion, a reversal from the 21.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.48 per share. Heading into earnings, analysts covering the company have mixed opinions about the business, with revenue estimates seeing 6 upward and 3 downward revisions over the last 30 days. JPMorgan Chase has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 2.2% on average. With JPMorgan Chase being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for banks stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.3% on average over the last month. JPMorgan Chase is up 6.2% during the same time and is heading into earnings with an average analyst price target of $291.54 (compared to the current share price of $287). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
This Stock Has Increased 4,720%: Here's Why It's Still a Buy
Johnson & Johnson has delivered excellent returns to its long-term shareholders. One key factor behind the company's success is its ability to innovate. Despite various challenges, the drugmaker's strong business and dividend program make it attractive. 10 stocks we like better than Johnson & Johnson › Time is one of investors' greatest allies. With enough patience, even a relatively small sum of money invested in an excellent company can yield substantial returns, especially when dividends are reinvested. Case in point: Shares of Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, have increased by 4,720% over the past few decades. The stock may have garnered more headlines due to various legal challenges over the past few years, but it remains an excellent long-term option, especially for income seekers. Here's the rundown. Medical care is always in high demand: So long as we get sick, this is one sector that will never disappear. However, specific companies in the industry can cease to exist. One reason they do is their failure to innovate. Even if healthcare never sleeps, it does evolve, and it's critical for companies aiming to be successful over the long run to keep pace with that evolution. Johnson & Johnson has done that admirably over the years. Consider its pharmaceutical segment. Last year, the drugmaker had more than 10 medicines that each generated over $1 billion in sales. In 2014, Johnson & Johnson also had more than 10 drugs that were blockbusters. Some of them were the same as last year's, but some weren't -- because the company has developed and marketed newer therapies over the past decade that have replaced older ones. In a decade, Johnson & Johnson's lineup of approved products will look different yet again. However, one thing won't change: It will still have many drugs that reach the $1 billion annual sales mark. J&J has more than 100 programs in its pipeline. True, many of those are for therapies seeking label expansions. But the company also has some brand-new clinical compounds, at least some of which will make it through the rigorous clinical-trial testing phases and go on to be massively successful. And we haven't even mentioned Johnson & Johnson's medtech business, where it markets a range of medical devices across several major therapeutic areas. Its operations are well diversified in the healthcare sector. That, combined with the company's innovative qualities, makes it likely to remain a leader in healthcare for a long time. Johnson & Johnson has encountered some headwinds in recent years. It's facing thousands of lawsuits from plaintiffs who allege that its talc-based products gave them cancer. The company has attempted to resolve these issues through various settlement proposals, but so far, to no avail. These legal battles are worth monitoring, but the stock is attractive despite them. The company is not at serious risk of bankruptcy. That's why it still has an AAA credit rating, which is even higher than that of the U.S. government. Several judges have shot down its attempts to settle these lawsuits via a bankruptcy maneuver through a subsidiary, partly because of the company's underlying financial strength. While it's hard to know how this saga will end, my view is that Johnson & Johnson will continue performing well long after the dust settles. Here's another potential challenge Johnson & Johnson faces: Some of its therapies will generate significantly less revenue in the next few years, due to either patent cliffs or Medicare price negotiations in the U.S. Here again, J&J can handle this threat. The company's innovative ability is the best way to overcome this problem. The healthcare specialist can also count on its medtech unit to pick up some of the slack. One attractive opportunity in this segment is within the robotic-assisted surgery (RAS) niche. Johnson & Johnson is developing its Ottava RAS system, which should grant it plenty of long-term revenue opportunities and help it navigate patent cliffs. Of course, we can't talk about J&J without mentioning its dividend. The company has increased its payouts for 62 consecutive years, which makes it a Dividend King. This streak highlights, once again, how strong Johnson & Johnson's business is -- most corporations don't even last six decades, let alone pay dividends for that long. The stock is an excellent pick for long-term, income-oriented investors. Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. This Stock Has Increased 4,720%: Here's Why It's Still a Buy was originally published by The Motley Fool
